Indeed, when we categorized our initial pathologically evaluated cohort using the exact same criteria as in [51], testing the association of APOE-ε4 with risk of AD–LB+ pathology yielded a modestly higher OR and nominal significance (OR = 1.46, P = 5.5 × 10−3) (Table 4). This evidence concerns the gene APOE and Alzheimer disease.